HK1206071A1 - Methods and compositions for providing a preeclampsia assessment - Google Patents

Methods and compositions for providing a preeclampsia assessment Download PDF

Info

Publication number
HK1206071A1
HK1206071A1 HK15106500.3A HK15106500A HK1206071A1 HK 1206071 A1 HK1206071 A1 HK 1206071A1 HK 15106500 A HK15106500 A HK 15106500A HK 1206071 A1 HK1206071 A1 HK 1206071A1
Authority
HK
Hong Kong
Prior art keywords
preeclampsia
methods
compositions
providing
find use
Prior art date
Application number
HK15106500.3A
Other languages
English (en)
Chinese (zh)
Inventor
J Butte Atul
Xuefeng Ling Bruce
Liu Miller Linda
A Morgan Alexander
Chen Gongxing
Ji Jun
Yang Ting
Original Assignee
The Board Of Trustees Of The Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Board Of Trustees Of The Leland Stanford Junior University filed Critical The Board Of Trustees Of The Leland Stanford Junior University
Publication of HK1206071A1 publication Critical patent/HK1206071A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6845—Methods of identifying protein-protein interactions in protein mixtures
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/689—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to pregnancy or the gonads
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/36—Gynecology or obstetrics
    • G01N2800/368—Pregnancy complicated by disease or abnormalities of pregnancy, e.g. preeclampsia, preterm labour

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Evolutionary Biology (AREA)
  • Theoretical Computer Science (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Public Health (AREA)
  • General Engineering & Computer Science (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Data Mining & Analysis (AREA)
  • Databases & Information Systems (AREA)
  • Epidemiology (AREA)
HK15106500.3A 2012-05-08 2013-05-07 Methods and compositions for providing a preeclampsia assessment HK1206071A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261644254P 2012-05-08 2012-05-08
US61/644,254 2012-05-08
US201261731640P 2012-11-30 2012-11-30
US61/731,640 2012-11-30
PCT/US2013/039918 WO2013169751A1 (en) 2012-05-08 2013-05-07 Methods and compositions for providing a preeclampsia assessment

Publications (1)

Publication Number Publication Date
HK1206071A1 true HK1206071A1 (en) 2015-12-31

Family

ID=49551212

Family Applications (2)

Application Number Title Priority Date Filing Date
HK15106500.3A HK1206071A1 (en) 2012-05-08 2013-05-07 Methods and compositions for providing a preeclampsia assessment
HK15107134.5A HK1206790A1 (en) 2012-05-08 2013-05-07 Methods and compositions for providing a preeclampsia assessment

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK15107134.5A HK1206790A1 (en) 2012-05-08 2013-05-07 Methods and compositions for providing a preeclampsia assessment

Country Status (7)

Country Link
US (1) US20150099655A1 (enExample)
EP (1) EP2847354A4 (enExample)
JP (1) JP2015519564A (enExample)
CN (1) CN104487593A (enExample)
GB (1) GB2515983A (enExample)
HK (2) HK1206071A1 (enExample)
WO (1) WO2013169751A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014160237A2 (en) * 2013-03-14 2014-10-02 The Board Of Trustees Of The Leland Stanford Junior University Methods of prognosing preeclampsia
WO2016019176A1 (en) * 2014-07-30 2016-02-04 Matthew Cooper Methods and compositions for diagnosing, prognosing, and confirming preeclampsia
CN107367618B (zh) * 2014-10-10 2020-02-14 韦恩州立大学 与胎儿绒毛外滋养层细胞测定有关的方法和组合物
EP3259600B1 (en) * 2015-02-18 2024-07-24 MirZyme Therapeutics Limited Diagnostic assay and treatment for preeclampsia
CA2977458A1 (en) * 2015-03-16 2016-09-22 A1M Pharma Ab Biomarkers for preeclampsia
WO2017075027A1 (en) * 2015-10-26 2017-05-04 Brigham Young University Serum lipid biomarkers of preeclampsia
JP7080176B2 (ja) * 2016-02-29 2022-06-03 エフ．ホフマン－ラ ロシュ アーゲー 子癇前症におけるマーカーとしてのｉｇｆｂｐ－７
EP3458861A4 (en) * 2016-05-17 2019-12-11 LDX Prognostics Limited Co. METHOD AND COMPOSITIONS FOR ASSESSING PRECLAMPSY
KR20240100488A (ko) 2016-06-07 2024-07-01 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 세균성 감염 및 바이러스성 감염의 진단 방법
GB201702792D0 (en) 2017-02-21 2017-04-05 Queens Univ Of Belfast A new biomarker for preeclampsia
US20200264188A1 (en) 2017-09-13 2020-08-20 Progenity, Inc. Preeclampsia biomarkers and related systems and methods
RU2691114C1 (ru) * 2018-03-20 2019-06-11 федеральное государственное бюджетное образовательное учреждение высшего образования "Ростовский государственный медицинский университет" Министерства здравоохранения Российской Федерации Способ прогнозирования развития преэклампсии в поздние сроки беременности
WO2020117184A1 (en) * 2018-12-02 2020-06-11 Binhai Industrial Technology Research Institute Of Zhejiang University Methods and compositions for providing a preeclampsia assessment by proteomics
CN110305954B (zh) * 2019-07-19 2022-10-04 广州市达瑞生物技术股份有限公司 一种早期准确检测先兆子痫的预测模型
EP4070113A4 (en) 2019-12-04 2023-12-20 Biora Therapeutics, Inc. ASSESSMENT OF PREECAMPSIA USING FREE AND DISSOCIATE PLACENTAL GROWTH FACTOR ASSAYS
KR102302742B1 (ko) * 2019-12-31 2021-09-15 의료법인 성광의료재단 임신중독증 진단용 바이오마커 조성물 및 이의 용도
US12426782B2 (en) 2020-11-06 2025-09-30 The Board Of Trustees Of The Leland Stanford Junior University Systems and temporal alignment methods for evaluation of gestational age and time to delivery
CN112946283B (zh) * 2021-01-29 2022-11-29 暨南大学 定量a2m的产品在制备子痫前期诊断工具中的应用
WO2022186821A1 (en) * 2021-03-02 2022-09-09 Mprobe Inc., Methods and compositions for providing a preeclampsia assessment using leptin and ceramide
CN113223714B (zh) * 2021-05-11 2022-07-05 吉林大学 一种用于预测子痫前期风险的基因组合、子痫前期风险预测模型及其构建方法
CN115308423B (zh) * 2022-10-10 2023-02-10 天津云检医疗器械有限公司 用于先兆子痫风险预测、评估或诊断的生物标志物、试剂盒及方法
EP4636095A1 (en) * 2022-12-16 2025-10-22 BGI Genomics Co., Limited Preeclampsia biomarker and use thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5009811B2 (ja) * 2004-12-21 2012-08-22 イェール ユニバーシティ 子癇前症の検出
CA3147058A1 (en) * 2005-03-18 2006-09-21 The Chinese University Of Hong Kong Markers for prenatal diagnosis, monitoring or predicting preeclampsia
EP1946121A2 (en) * 2005-10-27 2008-07-23 Yale University, Inc. Urinary proteomic biomarker patterns in preeclampsia
US20080071151A1 (en) * 2006-06-30 2008-03-20 Sogin David C Method and Apparatus for Diagnosing Pre-eclampsia
US20080233583A1 (en) * 2007-02-20 2008-09-25 Regents Of The University Of California Biomarkers for preeclampsia
US20090068683A1 (en) * 2007-06-11 2009-03-12 Mayo Foundation For Medical Education And Research Markers for preeclampsia
WO2009108073A1 (en) * 2008-02-28 2009-09-03 Auckland Uniservices Limited Biomarkers for prediction of preeclampsia and/or cardiovascular disease
CA2795776A1 (en) * 2010-04-06 2011-10-13 Caris Life Sciences Luxembourg Holdings, S.A.R.L. Circulating biomarkers for disease
JP2013524251A (ja) * 2010-04-13 2013-06-17 プロノタ エヌ．ヴェ． 妊娠高血圧疾患のバイオマーカー
CN103415769B (zh) * 2010-12-06 2017-04-12 迈卡蒂斯股份有限公司 用于妊娠性高血压疾病的生物标志物和参数
EP2766726A1 (en) * 2011-10-14 2014-08-20 Aarhus Universitet Diagnostic and prognostic use of prombp-complexes
WO2014160237A2 (en) * 2013-03-14 2014-10-02 The Board Of Trustees Of The Leland Stanford Junior University Methods of prognosing preeclampsia

Also Published As

Publication number Publication date
HK1206790A1 (en) 2016-01-15
CN104487593A (zh) 2015-04-01
EP2847354A1 (en) 2015-03-18
GB201420279D0 (en) 2014-12-31
GB2515983A (en) 2015-01-07
JP2015519564A (ja) 2015-07-09
WO2013169751A1 (en) 2013-11-14
US20150099655A1 (en) 2015-04-09
EP2847354A4 (en) 2015-12-30

Similar Documents

Publication Publication Date Title
HK1206790A1 (en) Methods and compositions for providing a preeclampsia assessment
HK1246828A1 (zh) 用於检测癌症的生物标志物组
WO2015009734A3 (en) Assays for antimicrobial activity and applications thereof
EA201590027A1 (ru) Способы детекции заболеваний или состояний
MX2013000917A (es) Metodos para detectar las enfermedades o condiciones usando celulas fagociticas.
WO2013190380A3 (en) Device context determination
GB201516569D0 (en) Methods, compositions, and kits for nucleic acid analysis
HK1206066A1 (en) Rapid antibiotic susceptibility testing
EP2860596A3 (en) Methods and apparatus relating to measurement instruments
CA2951016C (en) Prostate cancer detection kit or device, and detection method
WO2015094995A3 (en) Gene signature biomarkers of tumor response to pd-1 antagonists
MX2015010174A (es) Herramientas de diagnostico para predecir la presentacion de preeclampsia.
IL247375A0 (en) Detection and display of suspicious map displacements
NZ703411A (en) Use of markers in the diagnosis and treatment of prostate cancer
WO2013166558A8 (en) Diagnostic gene marker panel for colorectal cancer
WO2013106844A3 (en) Methods and compositions for the treatment and diaginosis of pancreatic cancer
WO2012170206A3 (en) Color-producing diagnostic systems, reagents and methods
EP3012326A4 (en) PRIMER AND PROBE SET FOR IDENTIFYING GENPOLYMORPHISM AND USE THEREOF
WO2014052616A3 (en) Insulated nanoelectrode-nanopore devices and related methods
EP3134552A4 (en) Methods, processes, devices and kits for the measurement of post traumatic stress disorder microrna markers
WO2015092046A3 (en) Prostate cancer biomarkers
HK1212392A1 (en) Genetic markers for mastitis resistance
WO2013106747A3 (en) Methods and compositions for the treatment and diagnosis of thyroid cancer
WO2016089732A3 (en) Methods and compositions for diagnosis and management of diabetes and metabolic syndrome
WO2015185672A3 (en) New markers for the assessment of an increased risk for mortality